Development of nanobody conjugate to cross blood brain barrier and treat brain tumors
Bubendorf, Switzerland, Thursday, May 20, 2021 - CIS Pharma has started the development of a nanobody against a novel tumor target. The antigen is homogeneously overexpressed in various forms of [...]